Q-omics provides the consensus-scored DDN profile across patient tissues and cancer cell-line models. DDN expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, DDN is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, DDN RNA expression shows 22,342 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, KIRC, and GBM as cancer lineages where DDN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDN survival associations across molecular data types. DDN RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDN RNA expression–survival associations across cancer types. High DDN expression shows unfavorable associations in ACC, KIRP, KIRC, MESO, KICH and BLCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for DDN RNA expression.
This table summarizes DDN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DDN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDN shows lower tumor expression in KIRC, KIRP and KICH and higher tumor expression in COAD, LUAD and BLCA. The KIRC box plot shows higher DDN RNA expression in normal versus tumor tissue (log2 FC = −4.026, t-test p < 0.001).
This table shows molecular features associated with DDN in patient tissues and cancer cell lines. In patient samples, DDN shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, DDN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
